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This Special Issue of Autoimmunity Reviews constitutes summaries
of  presentations  at  the  20th  International  Meeting  on  Immune
Pathology and Orphan Diseases, held in Torino, Italy, 25-28th January
2017. As such, these presentations represent the state of the art on
the pathophysiology of autoimmune diseases as well as the most
recent insights into the management of these pathologic conditions.
The latter includes both the optimal use of established drugs and
approaches  as  well  as  novel  knowledge  on  the  means  and
consequences  of  targeted  blocking  of  molecules  or  cellular
mechanisms. 
The 2nd Turin Congress on systemic idiopathic vasculitis concluded
the works of the International Meeting on Immune Pathology and
Orphan Diseases. 
This Satellite Congress was mainly addressed to the management of
antineutrophil  cytoplasm  antibody  (ANCA)-associated  vasculitis:
advances  on  induction  therapy  and  maintenance  treatment.
Guidelines are recommendations were critically discussed,  reviewing
available evidence providing experts’ insights.
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The papers in this Special Issue of Autoimmunity Reviews constitute
summaries  of  presentations  at  the  20th  International  Meeting on
Immune Pathology and Orphan Diseases, held in Torino, Italy, 25-
28th January 2017. As such, these presentations represent the state
of the art on the pathophysiology of autoimmune diseases as well as
the most recent insights into the management of these pathologic
conditions. The latter includes both the optimal use of established
drugs and approaches as well as novel knowledge on the means and
consequences  of  targeted  blocking  of  molecules  or  cellular
mechanisms.
Firstly,  Cimaz  and  co-workers  (1)  focused  on  the  treatment  of
juvenile idiopathic arthritis (JIA), reviewing the current therapeutic
approaches and highlighting the unmet needs. The management of
patients with JIA has significantly improved in the last 15 years due
to the introduction of biologic agents and the development of large
pediatric  rheumatology  research  networks  (e.g.  Paediatric
Rheumatology  InterNational  Trials  Organisation  (PRINTO),  the
-Pediatric  Rheumatology  Collaborative  Study  Group  and  the
Childhood  Arthritis  &  Rheumatology  Research  Alliance).
Nevertheless,  JIA  treatment  remains  challenging,  particularly  in
patients who fail to respond to the traditional agents and develop
early bone erosions or in those who suffered for frequent relapses.
Of interest, their review addresses hot topics in the management of
JIA, including the safety issues related to the switch among biologics
and  provides  the  Authors’  expert  opinion  about  an  important
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unsolved question: when and how withdrawal biological therapy in
patients with JIA. 
Rossi and colleagues (2) explored current and novel approaches for
the management of systemic sclerosis (SSc). The key message of
their  review  is  that  while  there  is  no  curative  therapy  for
scleroderma yet,  there  are  several  treatment  options  to  improve
both quality of life and survival of these patients. In this scenario,
early detection of disease and immediate intervention appears to
make a difference. It is important to appreciate that SSc is a highly
heterogeneous disease with both clinical and laboratory predictors
available  to  define  expected  disease  course.  Refined  clinical
phenotyping  and  careful  early  evaluation  for  active  occult  organ
disease are the keys to deciding appropriate treatment approach.  
The  challenging  management  of  idiopathic  inflammatory
myopathies  (IIMs)  is  discussed  by  Cavagna  and  co-workers  by
reviewing  the  current  available  guidelines  and  by  providing  their
expert  opinion  perspectives  (3).  They  carried  out  a  practical
evaluation of the current status of treatment in patients affected by
IIMs  by  highlighting  unmet  needs  and  focusing  on  established
approaches. A detailed therapeutic algorithm summarizing available
therapies  and  their  potential  areas  of  effectiveness  has  been
discussed. However, taken together, the data confirm how further
efforts  are  needed  in  order  to  improve  and  harmonize  the
therapeutic approach in patients with IIMs. 
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The management of Adult Onset Still’s Disease (AOSD) is described
by Govoni and colleagues (4). When putting together the available
evidences, they concluded that the best therapy for AOSD has not yet been
defined by recommendations or guidelines, and still  relies on the personal clinical
experience of the attending physician. Among the others, their main message relies on
the importance of quickly achieving the clinical remission, especially in the systemic
subset of the disease, once the diagnosis is confidently reached. While steroids and
conventional  DMARDs  still  remain  the  first  line  of  therapy, the  use  of  biologic
DMARDs (Ab anti-IL1, anti-IL6 and anti-TNF) has proven to be useful and can allow
physicians to obtain a complete and stable control of the disease when other therapies
failed. 
Special focus on ANCA-associated vasculitis
The 2nd Turin Congress on systemic idiopathic vasculitis concluded
the works of the International Meeting on Immune Pathology and
Orphan Diseases. This Satellite Congress was mainly addressed to
the  management  of  antineutrophil  cytoplasm  antibody  (ANCA)-
associated  vasculitis:  advances  on  induction  therapy  and
maintenance treatment.
ANCA-associated vasculitis include: Granulomatosis with Polyangiitis
(GPA),  Microscopic  Polyangiitis  (MPA),  and  Eosinophilic
Granulomatosis  with  Polyangiitis  (EGPA).  Renal-limited  ANCA-
associated  vasculitis  is  considered  a  kidney-limited  form of  MPA.
Several  studies  demonstrated  that  these  diseases  have  some
pathogenic similarities but different genetic associations  [5-11]. In
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the last few years, treatment strategies have been gradually better
defined, and several biologic agents have been studied, especially
the monoclonal anti-CD20 antibody Rituximab, in induction [12, 13]
and in  maintaining  [14] remission  in  severe GPA or  MPA setting.
Glucocorticoids  remain  the  cornerstone  of  therapy  for  ANCA-
associated  vasculitides,  but  efforts  are  still  ongoing  in  order  to
identify  potent  glucocorticoid-sparing  agents.  In  detail,  the  initial
dosage  of  glucocorticoids  for  patients  with  active  and  severe
disease  is  usually  1  mg/kg/day  prednisone-equivalent,  usually
preceded  by  1  to  3  boluses  of  methylprednisolone  (7.5  to  15
mg/kg/day). Presently, several centers aim to stop glucocorticoids at
6 months. 
Cyclophosphamide and Rituximab,  combined with  glucocorticoids,
are two main agents for remission induction in patients with severe
GPA  or  MPA.  These  drugs  can  induce  a  partial  response  or  a
complete remission in >80% of patients. For patients with severe
EGPA, data are too limited at this time to consider Rituximab only as
a potential alternative to cyclophosphamide as a front line therapy,
but  several  evidences  pointed  out  that  it  could  be  effective  in
refractory  cases  [15].  Cyclophosphamide  can  be  administered  as
intravenous pulses (boluses at regular intervals; 15 mg/kg, every 14
days for 1 month then every 3 weeks) or continuous oral tablets (2
mg/kg/day)  with  doses  adjusted  to  the  age  and  the  glomerular
filtration rate of the patient. Both administration routes are effective
in  achieving  remission,  but  oral  cyclophosphamide  is  associated
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with an increased frequency of neutropenia and infections, possibly
due to a higher cumulative dose, which is about 16 g compared with
8 g for “pulse” regimen for the 3-month duration therapy. Of note,
the risk of infertility and late complications (i.e., cancers of bladder
and skin,  and lymphomas)  is  linked with the cumulative dose as
well.  However, the use of oral cyclophosphamide is associated with
a lower subsequent relapse rate (20% instead of 40%) [16]. 
Rituximab  is  a  chimeric  monoclonal  antiCD20  antibody,  which
induces  a  sustained  peripheral  B-cells  depletion,  through  the
specific  binding  of  CD20  antigen  on  B-lymphocytes  surface.
Rituximab has been evaluated in two randomized trials (RAVE and
RITUXVAS)  and  subsequently  approved  as  an  alternative  to
cyclophosphamide followed by azatioprine to treat severe forms of
GPA and MPA in adults with a history of ANCA positivity [12,13]. In
these  two  studies,  Rituximab  was  found  to  be  not  inferior  to
cyclophosphamide in inducing remission at 6 months. The response
to Rituximab, compared to cyclophosphamide, may be superior in
relapsers who are Rituximab-naive and PR3-ANCA positive patients
as compared to MPO-ANCA positive ones [12]. Thus, when choosing
between  Rituximab  and  cyclophosphamide,  one  should  consider
several  potential  indications  to  Rituximab,  including  relapsing
disease,  protecting  fertility,  refractory  disease,  poorly  tolerated
cyclophosphamide,  malignancy  risks,  limiting  exposure  to
cyclophosphamide, c-ANCA positive disease. 
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In addition, plasma exchange (7 sessions over 2 weeks) combined
with induction treatment can be considered for patients with severe
ANCA-associated  vasculitis  with  active  glomerulonephritis  and/or
alveolar hemorrhage, and as a rescue treatment for patients who
did  not  satisfactorily  respond  to  the  induction  therapy  [17].
However, the benefits of this procedure in such patients have not
been formally and completely demonstrated. 
Following induction with cyclophosphamide (usually 3 or 6 months
of therapy), patients who achieve clinical remission can be switched
to  a  less  toxic  immunosuppressant  for  maintenance.  The
maintenance treatment should last at least 18–24 months [18]. The
most commonly used maintenance agent is azathioprine (2 mg/day,
orally) while mycophenolate mofetil was found to be associated with
higher relapse rate. Previous studies with maintenance for 1–3 years
showed that irrespective of the induction and maintenance regimen,
the relapse rate in GPA could reach 51%–64% at 7 years  [19]. The
preliminary results of the European REMAIN trial, which compared 2
vs  4  years  of  maintenance  with  azathioprine,  suggest  that  the
continuation of therapy for 4 years may be associated with a lower
relapse rate, in particular for patients with persistent ANCA positivity
at remission. 
The maintenance strategy following the Rituximab-based induction
treatment currently lacks consensus. In the RAVE trial, a multicenter
randomized double-blind study, no maintenance therapy was given
after the fourth Rituximab infusion. The relapse rates at 18 months
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were  comparable  between  the  Rituximab  and  the
cyclophosphamide–azathioprine  arms,  but  they  remained  at
approximately 30% [12]. 
Therefore,  several  options  are  eligible  following  Rituximab-based
induction therapy.  Some groups suggested that re-treatment with
Rituximab should be considered according to B-cells and/or CD19+
CD20+ lymphocytes count monitoring (with a repeat full course of
four  Rituximab  infusions  with  B-lymphocyte  reconstitution  and/or
ANCA reappearance or significant titer increase)  [20]. At the same
time, others reported the usefulness of a  systematic maintenance
infusions  of  Rituximab  at  regular  intervals,  every  6–12  months,
independently of ANCA status or B-cells count and using different
dosages  [21,22].   The French Vasculitis  Study Group MAINRITSAN
trial,  a  prospective  randomized  open-label  study  to  compare
azathioprine  and  Rituximab  (500  mg  every  6  months)  as  a
maintenance  therapy  following  a  glucocorticoid  plus
cyclophosphamide-based induction in GPA or MPA patients, found a
lower rate of major relapses with Rituximab at 28 months (5.3% vs
29.3%) [23]. Another international study (RITAZAREM) is evaluating
Rituximab,  1000  mg  every  4  months,  vs  azathioprine  as  a
maintenance therapy in relapsing ANCA-positive patients with GPA
or MPA following a glucocorticoid plus Rituximab-based induction. 
How I treat patients in clinical practice: 
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We have previously published the favorable outcome of 11 patients
with severe AAV treated with an improved “4+2” Rituximab protocol
[24].  This  therapeutic  approach  was  generally  well  tolerated and
allowed to avoid further immunosuppressive maintenance therapy
permitting tapering of oral prednisone to 5 mg/day by the end of the
3rd  month  after  Rituximab  administration.   Its  long-term  safety
profile has been demonstrated in a recent study [25] collecting data
of  patients  followed  for  a  mean  of  85  months  (range  45-132
months).
All  patients  given  the  “4+2”  Rituximab protocol  had  a  complete
peripheral  blood-B-cells  depletion.  The  CD20+  B-cells  were
detectable  in  the  circulation  after  a  mean of  11.5  months  (9–19
months). Of note, after 36 months, CD20+ cells count was still lower
than baseline (p < 0.01). 
A single cycle of “4+2” Rituximab protocol was able to maintain in
remission more than 60% of the patients for at  least 5 years.  In
detail, following a single cycle “4+2” Rituximab protocol, 4 out of 11
patients (37%) remained in remission with no relapse (median 66
months [60-108]). Seven patients relapsed after a remission period
of  54  months  (24-96)  and  were  similarly  re-treated.  Six  months
later, 6 of 7 (86%) were in complete remission, 1 (14%) in partial
remission.  After  the  second cycle  of  RTX these 7  patients  had a
complete  remission  over  a  median  of  32  months  (12-96)  of
observation. 
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The efficacy of  the “4+2” dose protocol  is  probably related to a
more  effective  tissue  depleting  activity  when  compared  to  the
standard scheme, providing  a   more prolonged clinical remission.  
As regard to the maintenance therapy, due to the delayed onset of
relapse,  this  experience  suggested  that  the  policy  of  monitoring
patients  could  be  better  than  to  administer  fixed  doses  of  RTX
whatever  the  clinical  assessment,  especially  in  MPO-positive
patients. Indeed, all 4 patients of our series relapsing in the first 5
years of follow-up after the first “4+2” Rituximab cycle were PR3
positive.
On the grounds of  this  experience we recently  introduced in  our
Department  a  therapeutic  algorithm  based  on  clinical  and
histological  presentation.  Briefly,  an  intensified  “4+2”  Rituximab-
protocol  is  administered  to  all  patients  with  ANCA-associated
vasculitis with biopsy-documented renal involvement. The protocol
consists of 3 Methylprednisolone pulses of 15 mg/Kg together with 4
Rituximab infusions of 375 mg/m2 weekly + 2 more doses at 1 and
2 months and oral corticosteroids 1 mg/kg tapered in 6 months. In
those patient with serum creatinine levels higher than 5 mg/dl and
more than 50% epithelial (florid) crescents at the renal biopsy (so
called  “crescentic  forms”)  2  bolus  dose (two weeks  apart)  of  15
mg/kg  cyclophosphamide,  adjusted  for  the  renal  impairment,  are
added  to  this  regimen  in  order  to  potentiate  the  CD20+ B-cells
depletion [16]. Plasma exchange (7 procedures) is performed in the
presence  of  alveolar  hemorrhage,  renal  rapidly  progressive
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impairment or dialysis dependence. No further immunosuppressive
maintenance  therapy  is  administered  and  corticosteroids  are
discontinued within the sixth month. CD20+ B-cells and ANCA are
strictly monitored. In case of CD20+ cells re-population and ANCA
increase (“biochemical flare”), a maintenance regimen of Rituximab
500 mg every 4 months for 2 years followed by 500 mg every 6
months for 1 year has been envisaged. A re-induction therapy with 4
Rituximab infusions of 375 mg/m2 weekly (instead of 6) and a faster
tapering of oral corticosteroids (aimed to discontinue the drug within
the third  month)  has  been reserved to  the case  of  frank  clinical
relapse. 
This  protocol  has  been  already  applied  to  12  MPA  patients  with
mean serum creatinine levels of 5.8 mg/dl.  Patients were meanly
followed for 14 months. At 6 months, 4 of them (3 having >50%
florid crescents and 1 with advanced, i.e., > 50%, glomerular global
sclerosis) were in dialysis. Eight patients (3 with >50% and 5 with
<50% florid crescents, including one case having >50% glomerular
sclerosis) were hemodialysis-free and in clinical remission. Four GPA
patients  were  followed  for  19  months.  One  of  2  patients  having
>50% florid crescents, who were oliguric at baseline, remained in
dialysis  at  the  sixth  month  of  observation.  All  4  GPA  patients
reached  a  complete  remission  of  extra-renal  involvement  with
disappearance of constitutional symptoms.
Concluding remarks
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These are only few of the aspects discussed during the Meeting, in
which all the participants were actively involved in vibrant debates.
It seems clear that what will be in the future seems to be now at our
door, with
novel targeted therapies and the upcoming personalized medicine
vigorously knocking.  Yet,  in this  crucial  moment,  we should learn
how  to  better  use  the  “old”  weapons.  While  a  growing  body  of
evidence coming from randomized control trials has recently paved
the way for the dissemination of guidelines and recommendation,
the management of rare, systemic, chronic autoimmune disease is
still challenging and suffers for unsolved questions. 
This is where the real-world data and the opinion of experts have a
role to play and the rationale behind the “How I  treat” approach
applied in this issue. 
Evidence-based  medicine  has  placed  a  general  priority  on
knowledge gained from clinical research for clinical decision-making.
However,  knowledge  derived  from  empiric,  population-based
research,  while  valued  for  its  ability  to  limit  bias,  is  not  directly
applicable  to  the  care  of  individual  patients.  The  gap  between
clinical research and individual patient care centers on the fact that
empiric research is not generally designed to answer questions of
direct  relevance  to  individual  patients.  Clinicians  must  use  other
forms  of  medical  knowledge,  including  pathophysiologic  rationale
and  clinical  experience,  in  order  to  achieve  the  best  medical
decision for a specific patient. In addition, physicians must elucidate
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and account for the goals and values of individual patients as well
as barriers and facilitators of care inherent in the system in which
they  practice.  In  a  complex  field  such  as  the  management  of
autoimmune evidence-based guidelines have to be filtered by the
prescribing  physicians’  clinical  judgment,  negotiating  potentially
conflicting  warrants  for  action,  in  an  effort  to  arrive  at  the  best
decision for a particular patient. 
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